Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Wound Heal, Scar, Keloid, Surgical Wound
Interventions: Vehicle Cream Base Emulsion Moisturizer + Petrolatum, FS2 Emulsion Moisturizer + Petrolatum; Other
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Contraception, Healthy Female
Interventions: Ulipristal acetate; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 14 more

Conditions: Fecal Incontinence, Bowel Incontinence
Interventions: Biofeedback, Injection; Behavioral · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Augusta, Georgia • Ann Arbor, Michigan + 3 more

Conditions: Anesthesia, Local, Photodamaged Skin, Topical and Infiltration Anesthetic Toxicity
Interventions: 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion, 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Parkinson's Disease (PD)
Interventions: Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Port Charlotte, Florida • Round Rock, Texas

Conditions: Pneumonia
Interventions: Cethromycin, Clarithromycin; Drug
Lead sponsor: Advanced Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Woodridge, Illinois

Conditions: Japanese Encephalitis
Interventions: ChimeriVax™-JE, JE-VAX®; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Chicago, Illinois • Shawnee Mission, Kansas • Missoula, Montana + 2 more

Conditions: Bacteremia
Interventions: Vancomycin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Heart Failure, Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Diabetes, Osteoporosis
Interventions: Multidisciplinary team interventions, Multidisciplinary team bimonthly visits either in person or via telephone., Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager; Other
Lead sponsor: Medco Health Solutions, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Kansas City, Missouri • St Louis, Missouri

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, Ceftriaxone, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Critical Illness
Interventions: Parenteral Nutrition, Propofol, Clevidipine, Dextrose-containing IV Fluids, Enteral feeding; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Arformoterol tartrate inhalation solution, Tiotropium; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more

Conditions: Kidney Transplant
Interventions: sirolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 18 more

Conditions: Back Pain
Interventions: Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS); Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1998
U.S. locations: 12
States / cities: Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more

Conditions: Seasonal Allergic Rhinitis
Interventions: GSP 301 NS, Olopatadine HCl NS, Mometasone furoate NS, GSP 301 Placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 37
States / cities: Mission Viejo, California • San Diego, California • San Jose, California + 28 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Cancer
Interventions: Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 25
States / cities: Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more

Conditions: Lice; Head Lice
Interventions: Medical Device (X92001483); Device
Lead sponsor: Oystershell NV; Industry
Eligibility: 1 Year and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Maitland, Florida

Conditions: Heart Transplant Failure and Rejection
Interventions: The Prospera™ Test; Diagnostic Test
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Prostate Cancer
Interventions: Prostate cancer treatment DESI; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years and older · Male only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Difference Between Femoral Nerve Block and Saphenous Block
Interventions: Study Technique, Control Technique; Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 40 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 416,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Otitis Media, Suppurative, Otitis Media, Purulent
Interventions: Telithromycin, Azithromycin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 6 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Blepharitis
Interventions: ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined), Azasite, Dexamethasone, Vehicle; Drug · Other
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Chandler, Arizona • Phoenix, Arizona • Glendale, California + 36 more

Search by objective public record fields.

Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions

Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

Fecal Incontinence Treatment (FIT) Study

Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

Coventry Outcomes Study of Seniors (COSS): A Comparative Effectiveness Study to Evaluate the Effect of a Multidisciplinary Team's Intervention on the Incidence of Nonelective Hospitalizations in a Medicare Population

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

The Energy Dose Study

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty

The DARE Warfarin CER Study

TELI COM - Telithromycin in Children With Otitis Media

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis